April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intraocular Treatment With Antisense Oligonucleotides Targeting Tumor Necrosis Factor-a In Murine Herpes Simplex Virus Type 1 Retinitis
Author Affiliations & Notes
  • Rafael S. Grajewski
    Ophthalmology, University Eye Clinic Cologne, Cologne, Germany
  • Jin Li
    Ophthalmology, St. Franziskus Hospital, Muenster; University of Duisburg-Essen, Muenster, Germany
  • Susanne Wasmuth
    Ophthalmology, St. Franziskus Hospital, Muenster; University of Duisburg-Essen, Muenster, Germany
  • Maren Hennig
    Ophthalmology, St. Franziskus Hospital, Muenster; University of Duisburg-Essen, Muenster, Germany
  • Dirk Bauer
    Ophthalmology, St. Franziskus Hospital, Muenster; University of Duisburg-Essen, Muenster, Germany
  • Arnd Heiligenhaus
    Ophthalmology, St. Franziskus Hospital, Muenster; University of Duisburg-Essen, Muenster, Germany
  • Footnotes
    Commercial Relationships  Rafael S. Grajewski, None; Jin Li, None; Susanne Wasmuth, None; Maren Hennig, None; Dirk Bauer, None; Arnd Heiligenhaus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2964. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rafael S. Grajewski, Jin Li, Susanne Wasmuth, Maren Hennig, Dirk Bauer, Arnd Heiligenhaus; Intraocular Treatment With Antisense Oligonucleotides Targeting Tumor Necrosis Factor-a In Murine Herpes Simplex Virus Type 1 Retinitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2964.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate whether inhibition of Tumor necrosis factor-alpha (TNF-a), one of the most potent pro-inflammatory cytokines, by intraocular TNF-a-antisense-oligonucleotides (ASON) affects the severity of HSV-retinitis in mice.

Methods: : To determine in vivo uptake of oligonucleotides after intraocular injection, FITC-labeled TNF-a ASON was used. HSV-retinitis was induced on day 0 by injecting HSV-1 (KOS strain) into the anterior chamber (AC) of the right eyes of BALB/c mice. The left contralateral eyes received an intraocular injection of TNF-a ASON on day 7. At the same time, control groups received sequence-unspecific ASON (CON) or buffer. The clinical course of retinitis, ocular inflammatory cell-infiltration (histology), TNF-a expression in the eye (ELISA), delayed-type hypersensitivity (DTH) reaction, virus-neutralizing antibody titers in the serum, HSV-specific proliferative responses of regional lymph node cells (uptake of 3H thymidine) and viral replication in the eyes were determined.

Results: : Strong in vivo fluorescence of FITC- TNF-a ASON was detected in the choroid and retina up to 3 days after intraocular injection, but none in the regional lymph node cells. The TNF-a ASON treatment reduced the expression of TNF-a in the eye, and suppressed the incidence and severity of retinitis on day 10 after infection (p<0.05). Systemic HSV-specific immunological parameters were not significantly influenced after TNF-a ASON treatment.

Conclusions: : The intraocular TNF-a ASON injection suppressed the ocular inflammatory cell infiltration and contralateral HSV-1 retinitis. This technical approach didn’t influence the systemic HSV-specific immune response or the antiviral protection.

Keywords: herpes simplex virus • retinitis • antiviral drugs 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×